Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, prospective, double-blind randomized controlled clinical trial.
The purpose is to evaluate the efficacy and safety of EGFR-TKI on residual GGOs after surgery
in patients with multiple primary lung cancers with ground glass nodules. This study is
expected to prove that compared with placebo in the control group, EGFR-TKI can significantly
reduce the residual GGOs lesions in patients with EGFR-positive multiple primary lung cancers
with ground-glass opacity, and bring a higher objective response rate (ORR), thus provides
new insights for treatment of these patients.
Phase:
Phase 2
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
First Affiliated Hospital of Zhejiang University Fujian Medical University Union Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University Tang-Du Hospital The First Affiliated Hospital of Nanchang University